Resistance surveillance in Italy: Four-year results from the MYSTIC program

R. Fontana, G. Lo Cascio, E. Giacobone, E. Romero, P. Cipriani, R. Sessa, Luigi Franchino

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The MYSTIC program is an international, multicenter surveillance study that compares the activity of meropenem, in centers that are prescribers, with that of imipenem, ceftazidime, piperacillin/tazobactam, ciprofloxacin and gentamicin. These Italian data are from 3 centers (neutropenia, cystic fibrosis and intensive care units). A total of 2,072 (238 Gram-positive and 1,834 Gram-negative) aerobic microorganisms were collected during the study. Pseudomonas aeruginosa (33.4%) was the most isolated species followed by Escherichia coli (14.4%). All except one Enterobacteriaceae strain isolated were fully susceptible to meropenem. Moreover, the activity of meropenem against Enterobacteriaceae was about eight-fold greater than that of imipenem and four- to eight-fold more active than that of ceftazidime. Meropenem was highly active against non-fermentative Gram-negative microorganisms, exceeding the activity of most of the other antimicrobial agents tested. Moreover, meropenem showed increasing activity during the 4 years of study (starting from 86.2% in 1997 to 94.0% in 2000). In conclusion, our results indicate that meropenem has excellent potency and spectrum of activity despite being prescribed for the treatment of seriously ill patients, and appears to be a reliable option for the initial empirical treatment of serious nosocomial infections.

Original languageEnglish
Pages (from-to)323-331
Number of pages9
JournalJournal of Chemotherapy
Volume14
Issue number4
Publication statusPublished - Aug 2002

Fingerprint

meropenem
Italy
Ceftazidime
Imipenem
Enterobacteriaceae
Ciprofloxacin
Cross Infection
Anti-Infective Agents
Gentamicins
Neutropenia
Cystic Fibrosis
Pseudomonas aeruginosa
Multicenter Studies
Intensive Care Units
Escherichia coli

Keywords

  • Antimicrobial activity
  • Meropenem
  • MYSTIC program
  • Nosocomial infections
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Fontana, R., Lo Cascio, G., Giacobone, E., Romero, E., Cipriani, P., Sessa, R., & Franchino, L. (2002). Resistance surveillance in Italy: Four-year results from the MYSTIC program. Journal of Chemotherapy, 14(4), 323-331.

Resistance surveillance in Italy : Four-year results from the MYSTIC program. / Fontana, R.; Lo Cascio, G.; Giacobone, E.; Romero, E.; Cipriani, P.; Sessa, R.; Franchino, Luigi.

In: Journal of Chemotherapy, Vol. 14, No. 4, 08.2002, p. 323-331.

Research output: Contribution to journalArticle

Fontana, R, Lo Cascio, G, Giacobone, E, Romero, E, Cipriani, P, Sessa, R & Franchino, L 2002, 'Resistance surveillance in Italy: Four-year results from the MYSTIC program', Journal of Chemotherapy, vol. 14, no. 4, pp. 323-331.
Fontana R, Lo Cascio G, Giacobone E, Romero E, Cipriani P, Sessa R et al. Resistance surveillance in Italy: Four-year results from the MYSTIC program. Journal of Chemotherapy. 2002 Aug;14(4):323-331.
Fontana, R. ; Lo Cascio, G. ; Giacobone, E. ; Romero, E. ; Cipriani, P. ; Sessa, R. ; Franchino, Luigi. / Resistance surveillance in Italy : Four-year results from the MYSTIC program. In: Journal of Chemotherapy. 2002 ; Vol. 14, No. 4. pp. 323-331.
@article{34479a04c3974bb9a8f16612f1e08719,
title = "Resistance surveillance in Italy: Four-year results from the MYSTIC program",
abstract = "The MYSTIC program is an international, multicenter surveillance study that compares the activity of meropenem, in centers that are prescribers, with that of imipenem, ceftazidime, piperacillin/tazobactam, ciprofloxacin and gentamicin. These Italian data are from 3 centers (neutropenia, cystic fibrosis and intensive care units). A total of 2,072 (238 Gram-positive and 1,834 Gram-negative) aerobic microorganisms were collected during the study. Pseudomonas aeruginosa (33.4{\%}) was the most isolated species followed by Escherichia coli (14.4{\%}). All except one Enterobacteriaceae strain isolated were fully susceptible to meropenem. Moreover, the activity of meropenem against Enterobacteriaceae was about eight-fold greater than that of imipenem and four- to eight-fold more active than that of ceftazidime. Meropenem was highly active against non-fermentative Gram-negative microorganisms, exceeding the activity of most of the other antimicrobial agents tested. Moreover, meropenem showed increasing activity during the 4 years of study (starting from 86.2{\%} in 1997 to 94.0{\%} in 2000). In conclusion, our results indicate that meropenem has excellent potency and spectrum of activity despite being prescribed for the treatment of seriously ill patients, and appears to be a reliable option for the initial empirical treatment of serious nosocomial infections.",
keywords = "Antimicrobial activity, Meropenem, MYSTIC program, Nosocomial infections, Pseudomonas aeruginosa",
author = "R. Fontana and {Lo Cascio}, G. and E. Giacobone and E. Romero and P. Cipriani and R. Sessa and Luigi Franchino",
year = "2002",
month = "8",
language = "English",
volume = "14",
pages = "323--331",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "4",

}

TY - JOUR

T1 - Resistance surveillance in Italy

T2 - Four-year results from the MYSTIC program

AU - Fontana, R.

AU - Lo Cascio, G.

AU - Giacobone, E.

AU - Romero, E.

AU - Cipriani, P.

AU - Sessa, R.

AU - Franchino, Luigi

PY - 2002/8

Y1 - 2002/8

N2 - The MYSTIC program is an international, multicenter surveillance study that compares the activity of meropenem, in centers that are prescribers, with that of imipenem, ceftazidime, piperacillin/tazobactam, ciprofloxacin and gentamicin. These Italian data are from 3 centers (neutropenia, cystic fibrosis and intensive care units). A total of 2,072 (238 Gram-positive and 1,834 Gram-negative) aerobic microorganisms were collected during the study. Pseudomonas aeruginosa (33.4%) was the most isolated species followed by Escherichia coli (14.4%). All except one Enterobacteriaceae strain isolated were fully susceptible to meropenem. Moreover, the activity of meropenem against Enterobacteriaceae was about eight-fold greater than that of imipenem and four- to eight-fold more active than that of ceftazidime. Meropenem was highly active against non-fermentative Gram-negative microorganisms, exceeding the activity of most of the other antimicrobial agents tested. Moreover, meropenem showed increasing activity during the 4 years of study (starting from 86.2% in 1997 to 94.0% in 2000). In conclusion, our results indicate that meropenem has excellent potency and spectrum of activity despite being prescribed for the treatment of seriously ill patients, and appears to be a reliable option for the initial empirical treatment of serious nosocomial infections.

AB - The MYSTIC program is an international, multicenter surveillance study that compares the activity of meropenem, in centers that are prescribers, with that of imipenem, ceftazidime, piperacillin/tazobactam, ciprofloxacin and gentamicin. These Italian data are from 3 centers (neutropenia, cystic fibrosis and intensive care units). A total of 2,072 (238 Gram-positive and 1,834 Gram-negative) aerobic microorganisms were collected during the study. Pseudomonas aeruginosa (33.4%) was the most isolated species followed by Escherichia coli (14.4%). All except one Enterobacteriaceae strain isolated were fully susceptible to meropenem. Moreover, the activity of meropenem against Enterobacteriaceae was about eight-fold greater than that of imipenem and four- to eight-fold more active than that of ceftazidime. Meropenem was highly active against non-fermentative Gram-negative microorganisms, exceeding the activity of most of the other antimicrobial agents tested. Moreover, meropenem showed increasing activity during the 4 years of study (starting from 86.2% in 1997 to 94.0% in 2000). In conclusion, our results indicate that meropenem has excellent potency and spectrum of activity despite being prescribed for the treatment of seriously ill patients, and appears to be a reliable option for the initial empirical treatment of serious nosocomial infections.

KW - Antimicrobial activity

KW - Meropenem

KW - MYSTIC program

KW - Nosocomial infections

KW - Pseudomonas aeruginosa

UR - http://www.scopus.com/inward/record.url?scp=0036693984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036693984&partnerID=8YFLogxK

M3 - Article

C2 - 12420847

AN - SCOPUS:0036693984

VL - 14

SP - 323

EP - 331

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 4

ER -